Abstract:Background. Plasma S100A1 protein is a novel inflammatory biomarker associated with acute myocardial infarction and neurodegenerative disease's pathophysiological mechanisms. This study aimed to determine the levels of this protein in patients with acute ischemic stroke early in the disease progression and to investigate its role in the pathogenesis of acute ischemic stroke.Methods. A total of 192 participants from hospital stroke centers were collected for the study. Clinically pertinent data were recorded. The volume of the cerebral infarction was calculated according to the Pullicino formula. Multivariate logistic regression analysis was used to select independent influences. ROC curve was used to analyze the diagnostic value of AIS and TIA. The correlation between S100A1, NF -KB p65, and IL-6 levels and cerebral infarction volume was detected by Pearson correlation analysis.Results. There were statistically significant differences in S100A1, NF -KB p65, and IL-6 among the AIS,TIA, and PE groups (S100A1, [230.96 +/- 39.37] vs [185.85 +/- 43.24] vs [181.47 +/- 27.39], P < 0.001; NF -KB p65, [3.99 +/- 0.65] vs [3.58 +/- 0.74] vs [3.51 +/- 0.99], P = 0.001; IL-6, [13.32 +/- 1.57] vs [11.61 +/- 1.67] vs [11.42 +/- 2.34], P < 0.001). Multivariate logistic regression analysis showed that S100A1 might be an independent predictive factor for the diagnosis of disease (P < 0.001). The AUC of S100A1 for diagnosis of AIS was 0.818 (P < 0.001, 95% CI [0.749-0.887], cut off 181.03, J max 0.578, Se 95.0%, Sp 62.7%). The AUC of S100A1 for diagnosis of TIA was 0.720 (P = 0.001, 95% CI [0.592-0.848], cut off 150.14, J max 0.442, Se 50.0%, Sp 94.2%). There were statistically significant differences in S100A1, NF -KB p65, and IL-6 among the SCI,MCI, and LCI groups (S100A1, [223.98 +/- 40.21] vs [225.42 +/- 30.92] vs [254.25 +/- 37.07], P = 0.001; NF -KB p65, [3.88 +/- 0.66] vs [3.85 +/- 0.64] vs [4.41 +/- 0.45], P < 0.001; IL-6, [13.27 +/- 1.65] vs [12.77 +/- 1.31] vs [14.00 +/- 1.40], P = 0.007). Plasma S100A1, NF -KB p65, and IL-6 were significantly different from cerebral infarction volume (S100A1, r = 0.259, P = 0.002; NF -KB p65, r = 0.316, P < 0.001; IL-6, r = 0.177, P = 0.036). There was a positive correlation between plasma S100A1 and IL-6 with statistical significance (R = 0.353, P < 0.001). There was no significant positive correlation between plasma S100A1 and NF -KB p65 (R < 0.3), but there was statistical significance (R = 0.290, P < 0.001). There was a positive correlation between IL-6 and NF -KB p65 with statistical significance (R = 0.313, P < 0.001).Conclusion. S100A1 might have a better diagnostic efficacy for AIS and TIA. S100A1 was associated with infarct volume in AIS, and its level reflected the severity of acute cerebral infarction to a certain extent. There was a correlation between S100A1 and IL-6 and NF -KB p65, and it was reasonable to speculate that this protein might mediate the inflammatory response through the NF -KB pathway during the pathophysiology of AIS.

Utility of serum amyloid A as a potential prognostic biomarker of acute primary basal ganglia hemorrhage

High S100B Levels in Cerebrospinal Fluid and Peripheral Blood of Patients with Acute Basal Ganglial Hemorrhage Are Associated with Poor Outcome.

Predictive Value of Serum Caspase-Cleaved Cytokeratin-18 Concentrations after Acute Intracerebral Hemorrhage

Elevated Serum CCL23 Levels at Admission Predict Delayed Cerebral Ischemia and Functional Outcome after Aneurysmal Subarachnoid Hemorrhage

Potential role of serum substance P as a favorable biomarker of functional outcome in acute spontaneous intracerebral hemorrhage

Serum lipoprotein-associated phospholipase A2 as a promising prognostic biomarker in association with 90-day outcome of acute intracerebral hemorrhage

Prognostic Utility of Serum Biomarkers in Intracerebral Hemorrhage: A Systematic Review

Usability of serum annexin A7 as a biochemical marker of poor outcome and early neurological deterioration after acute primary intracerebral hemorrhage: A prospective cohort study

Serum YKL-40 as a Predictive Biomarker of Cerebral Amyloid Angiopathy-Related Intracerebral Hemorrhage Recurrence

Levels of Interleukin-1β, Interleukin-18, and Tumor Necrosis Factor-α in Cerebrospinal Fluid of Aneurysmal Subarachnoid Hemorrhage Patients May Be Predictors of Early Brain Injury and Clinical Prognosis

Elevated HMGB1 and sRAGE levels in cerebrospinal fluid of aneurysmal subarachnoid hemorrhage patients

Determination of serum neutrophil gelatinase-associated lipocalin as a prognostic biomarker of acute spontaneous intracerebral hemorrhage

Admission Homocysteine as a Potential Predictor for Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage

Clinical Relevance of Cleaved RAGE Plasma Levels As a Biomarker of Disease Severity and Functional Outcome in Aneurysmal Subarachnoid Hemorrhage.

The Use of Serum Matrix Metalloproteinases in Cerebral Amyloid Angiopathy-Related Intracerebral Hemorrhage and Cognitive Impairment.

Effects of cerebral hemorrhage on the levels of SAA in serum

Serum Markers of Blood-Brain Barrier Remodeling and Fibrosis as Predictors of Etiology and Clinicoradiologic Outcome in Intracerebral Hemorrhage

Serum Soluble Tumor Necrosis Factor-Like Weak Inducer of Apoptosis is a Potential Biomarker for Outcome Prediction of Patients with Aneurysmal Subarachnoid Hemorrhage.

Diagnostic value and mechanism of plasma S100A1 protein in acute ischemic stroke: a prospective and observational study

Serum amyloid A1 protein in the prediction of acute myocardial infarction

Usability of serum AIM2 as a predictive biomarker of stroke-associated pneumonia and poor prognosis after acute supratentorial intracerebral hemorrhage: A prospective longitudinal cohort study